Samsung Biologics is taking part for the first time in the American Association for Cancer Research (AACR), one of the world’s largest cancer conferences. With AACR focused on preclinical and early clinical-stage research, the company aims to promote its contract research, development and manufacturing (CRDMO) capabilities and win clients in the early phases of drug development.
According to the industry on April 20, AACR is considered one of the world’s three major cancer meetings, along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). This year’s event is expected to draw more than 22,000 cancer researchers and pharmaceutical and biotech industry participants from about 140 countries. The meeting runs April 17-22 (local time) at the San Diego Convention Center in California.
Samsung Biologics said it is seeking to secure early-stage customers by starting collaboration when demand is high for contract research (CRO) and contract development (CDO), then carrying projects through to commercial production — an approach it described as an “early lock-in” strategy.
Jung Hyung-nam, vice president and head of Samsung Biologics’ Bio Research Center, said the company will “provide CRO and CDO services from the early development stage of innovative new drugs and establish ourselves as a trusted partner in drug development.”
At AACR, Samsung Biologics has prepared a promotional booth as well as oral and poster presentations.
On April 21, Alexis Santana, organoid sales director, will present on “Samsung Organoid: Enhancing Clinical Relevance in Anticancer Drug Development,” outlining how organoid services with high patient similarity could improve the success rate of drug development.
The company will also present posters featuring data showing that Samsung Organoid reproduces patients’ genetic characteristics and drug responses and demonstrates a high correlation with clinical outcomes, along with a separate poster on the therapeutic and manufacturing efficiency of its bispecific antibody platform, S-DUAL.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.